MENU

Can Emerson Electric (EMR) Stock Reach $185?

a developer of process controls systems, valves and analytical instruments

A.I.Advisor
published price charts
A.I.Advisor
Nov 02, 2026

Can Emerson Electric (EMR) Stock Reach $185?

Key Takeaways

  • The central target of $185 is the rounded average of verified analyst price targets that sit above the current share price, rather than an overall consensus.
  • The overall analyst mean is closer to $175, with a wide range spanning roughly $104 to $208, reflecting sharply divided views.
  • Emerson Electric Co. (EMR) last traded near $164.94, so reaching $185 would require a gain of roughly 12%.
  • Support comes from the company's shift toward automation and industrial software, including AspenTech, plus AI-driven demand and recent earnings momentum.
  • The biggest risks are a stretched valuation near 36x trailing earnings, mixed analyst ratings (including at least one Sell), and sensitivity to industrial capital spending.
  • Readers can explore Major News, Today's Price Move, a Forecast, and Earnings data for deeper, up-to-date context on EMR.
  • For automated market analysis, explore Trending AI Robots to monitor signals and trends across thousands of securities.

Analyst Price Targets and Consensus View

Emerson Electric Co. (NYSE: EMR) is a diversified industrial technology and software company, not an ETF. Aggregators report roughly 20 to 30 analysts covering the stock, and the overall average analyst price target clusters near $175 (sources range from about $172 to $181), with a Buy-leaning consensus. Because that mean sits only about 6% above the recent price, it does not represent a meaningful upside threshold on its own.

The $185 central target is therefore calculated differently: it is the rounded average of the individual analyst targets that are above the current share price. Those bullish targets span roughly $170 to $208, with recent actions including J.P. Morgan ($169 to $184), Mizuho ($173 to $180), RBC Capital ($188), Bernstein ($186), Evercore ISI ($190), Wells Fargo's Overweight initiation at $177, UBS ($180), and Citi ($182). More cautious views include Morgan Stanley's Sell at $145 and a Neutral $145 from DA Davidson, while the full published range runs from roughly $104 to $208. The breadth of that range shows genuine disagreement about valuation and the pace of the company's software transition.

Current Market Position and Path Toward the Target

EMR last closed near $164.94, close to its 52-week high of roughly $171 after a strong run from the mid-$120s earlier in the year. Reaching $185 implies a rise of about 12%, a substantial but not extreme move for a stock that has already advanced sharply. The path would likely depend on continued execution of Emerson's pivot toward higher-margin automation and industrial software, sustained AI-related demand in process and discrete industries, and margin expansion, all of which would need to offset an elevated valuation around 36x trailing earnings.

What Could Support a Move Toward the Target

  • Portfolio transformation: Emerson has consolidated Aspen Technology and repositioned around automation and software, which carries higher margins and recurring revenue potential.
  • Earnings momentum: Recent quarterly results beat expectations, with revenue up roughly 7% year over year and EPS growth in the low-to-mid 20% range.
  • AI and automation demand: Analysts cite AI-driven capital spending and process-automation demand as structural tailwinds supporting higher long-term earnings.
  • Positive revisions: Several firms raised targets in recent months, signaling improving confidence in the earnings and cash-flow outlook.

What Could Prevent the Target From Being Reached

  • Valuation: A trailing P/E (price-to-earnings ratio) near 36x and price-to-book near 4.5x leave limited room for disappointment and invite multiple compression.
  • Execution risk: The software integration and AspenTech consolidation must deliver the promised margin and growth benefits.
  • Cyclical demand: A slowdown in industrial capital spending or process-industry investment would pressure orders and revenue growth.
  • Divided Street: The presence of a Sell rating and several Neutral targets signals that not all analysts believe current growth justifies the valuation.

Technical Levels and Market Structure

EMR has been in a firm uptrend, recently touching a 52-week high near $171 before pulling back about 3% to the mid-$160s. That $170–$171 zone is the nearest resistance level, followed by the $175 area and the $180–$185 analyst-target cluster. On the downside, the recent $160 consolidation zone is an initial support level, with more durable support near $145–$150, which aligns with the cautious analyst targets. A sustained move through $171 would be a necessary first step toward the $185 objective.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms apply different assumptions. The most immediate catalyst is Emerson's fiscal fourth-quarter earnings report, expected around November 4, 2026, along with guidance for the coming fiscal year. Investors should also monitor analyst target revisions, AI-related order commentary, industrial capital-spending data, and margin trends in the software and automation segments. No single data point will determine whether the target is reached, and no definitive forecast should be assumed.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This allows traders to screen for emerging opportunities, keep an eye on existing positions, and detect changing trends more efficiently than manual review. Traders seeking a data-driven edge in names like EMR may find these automated signals a useful complement to fundamental research.

Final Assessment

The $185 target represents the rounded average of analyst price targets above the current share price, rather than an official published consensus. Reaching it would require a gain of roughly 12% from recent levels near $165. The strongest supports are Emerson's automation and software repositioning, AI-related demand, and improving earnings, while the principal obstacles are a demanding valuation, execution risk in the AspenTech integration, and genuine analyst disagreement that spans from Sell to aggressive Buy ratings. With earnings due in early November, guidance and order commentary will be the most important near-term signals for whether EMR can build toward that objective.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

EMR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EMR has been closely correlated with AME. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if EMR jumps, then AME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EMR
1D Price
Change %
EMR100%
+1.79%
AME - EMR
74%
Closely correlated
+0.33%
IR - EMR
70%
Closely correlated
+0.65%
ROK - EMR
70%
Closely correlated
+1.18%
LECO - EMR
69%
Closely correlated
-1.15%
GTES - EMR
66%
Closely correlated
+2.04%
More

Groups containing EMR

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EMR
1D Price
Change %
EMR100%
+1.79%
EMR
(6 stocks)
82%
Closely correlated
-2.75%
Producer Manufacturing
(346 stocks)
14%
Poorly correlated
+11.92%